Piramal Pharma Limited (NSE: PPLPHARMA)
India flag India · Delayed Price · Currency is INR
252.20
-9.40 (-3.59%)
Dec 20, 2024, 3:30 PM IST

Piramal Pharma Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Mar '24 Mar '23 Mar '22 Mar '21
Market Capitalization
334,354170,52881,683--
Market Cap Growth
124.88%108.77%---
Enterprise Value
378,134209,922130,128--
Last Close Price
252.20128.8166.80--
PE Ratio
737.60956.95---
Forward PE
77.3142.3340.39--
PS Ratio
3.822.091.15--
PB Ratio
4.242.161.21--
P/TBV Ratio
8.144.713.51--
P/FCF Ratio
-58.30---
P/OCF Ratio
44.5816.9816.88--
PEG Ratio
1.581.581.35--
EV/Sales Ratio
4.342.571.84--
EV/EBITDA Ratio
27.1918.4322.58--
EV/EBIT Ratio
57.7145.62---
EV/FCF Ratio
-1218.2171.77---
Debt / Equity Ratio
0.610.600.830.620.54
Debt / EBITDA Ratio
3.614.009.213.632.30
Debt / FCF Ratio
-16.10---
Asset Turnover
0.580.550.520.57-
Inventory Turnover
1.541.691.941.87-
Quick Ratio
0.430.610.640.690.82
Current Ratio
1.031.251.261.341.47
Return on Equity (ROE)
0.58%0.24%-2.77%6.11%-
Return on Assets (ROA)
2.46%1.93%-0.20%2.96%-
Return on Capital (ROIC)
2.95%2.30%-0.24%3.60%-
Earnings Yield
0.14%0.10%-2.28%--
FCF Yield
-0.09%1.72%-5.89%--
Dividend Yield
0.04%0.09%---
Payout Ratio
0.00%--13.30%-
Buyback Yield / Dilution
-9.21%-7.85%-0.95%-87.83%-
Total Shareholder Return
-9.16%-7.76%-0.95%-87.83%-
Source: S&P Capital IQ. Standard template. Financial Sources.